US 12,227,548 B2
Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
Laurie H. Glimcher, Boston, MA (US); and Han Dong, Boston, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 17/294,477
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Nov. 11, 2019, PCT No. PCT/US2019/060749
§ 371(c)(1), (2) Date May 17, 2021,
PCT Pub. No. WO2020/106483, PCT Pub. Date May 28, 2020.
Claims priority of provisional application 62/800,706, filed on Feb. 4, 2019.
Claims priority of provisional application 62/769,265, filed on Nov. 19, 2018.
Prior Publication US 2022/0023341 A1, Jan. 27, 2022
Int. Cl. C07K 14/47 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12Q 1/6886 (2018.01)
CPC C07K 14/4705 (2013.01) [A61K 39/4613 (2023.05); A61K 39/4644 (2023.05); A61K 39/464838 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12N 5/0646 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12Q 1/6886 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/57 (2023.05); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method of treating a subject having a condition that would benefit from upregulation of an immune response comprising administering to the subject a therapeutically effective amount of a composition comprising natural killer (NK) cells modified to increase the copy number of XBP1.